Roxithromycin dry suspension
Function and Efficacy
This product is a new generation of macrolide antibiotics, mainly acting on Gram-positive bacteria, anaerobic bacteria, chlamydia and mycoplasma. Its in vitro antibacterial effect is similar to that of erythromycin, and its activity against streptococci, Haemophilus ducreyi, Chlamydia trachomatis, Mycoplasma pneumoniae, oral or vaginal anaerobic bacteria is similar to that of erythromycin; its effect on Campylobacter, Bordetella pertussis and Haemophilus influenzae is not as good as that of erythromycin; it also has an inhibitory effect on Mycobacterium tuberculosis, most atypical mycobacteria, Campylobacter jejuni, Corynebacterium diphtheriae, and Pasteurella multocida; it has no antibacterial activity against G bacteria. Some bacteria have cross-resistance to erythromycin and this product, and this product is particularly effective against mycoplasma, chlamydia and Legionella infections. Its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.
Ingredients
The main ingredient of this product is: Roxithromycin.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| RoxithromycinIngredients |
This product is a new generation of macrolide antibiotics, mainly acting on Gram-positive bacteria, anaerobic bacteria, chlamydia and mycoplasma. Its in vitro antibacterial effect is similar to that of erythromycin, and its activity against streptococci, Haemophilus ducreyi, Chlamydia trachomatis, Mycoplasma pneumoniae, oral or vaginal anaerobic bacteria is similar to that of erythromycin; its effect on Campylobacter, Bordetella pertussis and Haemophilus influenzae is not as good as that of erythromycin; it also has an inhibitory effect on Mycobacterium tuberculosis, most atypical mycobacteria, Campylobacter jejuni, Corynebacterium diphtheriae, and Pasteurella multocida; it has no antibacterial activity against G bacteria. Some bacteria have cross-resistance to erythromycin and this product, and this product is particularly effective against mycoplasma, chlamydia and Legionella infections. Its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin. More |
80214-83-1 | 28 |
Appearance
This product is white or off-white powder with aromatic odor and sweet taste.
Indication
1. Suitable for the following infections caused by sensitive strains: (1) Upper respiratory tract infection. (2) Lower respiratory tract infection. (3) Ear, nose and throat infection. (4) Genital infection (except gonococcal infection). (5) Skin and soft tissue infection. 2. Can also be used for mycoplasma pneumonia, Chlamydia trachomatis infection and Legionnaires' disease, etc.
Usage and Dosage
Oral: 1 Adults: 0.15 g once, twice a day, or as directed by a physician. 2 Children: (1) Children weighing 6-11 kg, 25 mg each morning and evening, or as directed by a physician. (2) Children weighing 12-23 kg, 50 mg each morning and evening, or as directed by a physician. (3) Children weighing 24-40 kg, 100 mg each morning and evening, or as directed by a physician.
Adverse Reactions
1. Gastrointestinal reactions may occur: nausea, vomiting, loss of appetite, abdominal pain. 2. Abnormal liver function may occur: elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST). 3. Skin rash may occur.
Precautions
It is contraindicated for those who are allergic to this product.
Special Population Medication
Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: Not yet clear.
Drug Interactions
Not yet clear.
Storage
Sealed, store in a cool, dark and dry place.
Packaging Specification
50mg
Validity Period
24 months
Manufacturer
Xinhua Pharmaceutical (Gaomi) Co., Ltd.
-
Founded in:
2000-12-29 -
Address:
No. 6, Gaoxin 2nd Road (West), Gaomi High-tech Industrial Development Zone, Gaomi City, Weifang City, Shandong Province -
Tax NO.:
913707857262322817 -
Registered Funds:
19 million yuan -
Website:
-
Email: